MedTrace Logo

Safety and Immunogenicity of A/H1N1v Vaccines in Healthy Adults

NCT00943358 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 175

Last updated 2012-08-08

No results posted yet for this study

Summary

The purpose of this study is to evaluate the antibody response to one and two doses of influenza A/H1N1v vaccine in healthy adults.

Conditions

Interventions

BIOLOGICAL

MF59 H1N1 vaccine

3.75-7.5ug dose

BIOLOGICAL

Plain H1N1 vaccine

7.5-15ug

Sponsors & Collaborators

  • Public Health England

    collaborator OTHER_GOV

  • Novartis Vaccines

    collaborator INDUSTRY

  • University Hospitals, Leicester

    lead OTHER

Principal Investigators

  • Iain Stephenson, FRCP · University Hospitals, Leicester

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2009-09-30
Completion
2009-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00943358 on ClinicalTrials.gov